Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses

Arthritis and Rheumatism

Volumn 63, Issue 8, 2011, Pages 2445-2455

  Hou, Li Fei ^a   He, Shi Jun ^a   Li, Xin ^a   Yang, Yang ^b   He, Pei Lan ^a   Zhou, Yu ^a   Zhu, Feng Hua ^a   Yang, Yi Fu ^b   Li, Ying ^a   Tang, Wei ^a   Zuo, Jian Ping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ DERIVATIVE; DOUBLE STRANDED DNA ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 4; SM 934; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENZYME SYNTHESIS; EX VIVO STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY INJURY; LUPUS ERYTHEMATOSUS; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REGULATORY T LYMPHOCYTE; SPLEEN SIZE; SPLENOMEGALY; SURVIVAL; TH1 CELL; TH17 CELL; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ARTEMISININS; DISEASE MODELS, ANIMAL; FEMALE; INTERFERON-GAMMA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; TH1 CELLS; TH17 CELLS; TREATMENT OUTCOME;

EID: 79961112281     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30392     Document Type: Article

References (41)

1. Theofilopoulos AN, Dixon FJ,. Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: 269-90.
2. Reilly CM, Gilkeson GS,. Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL/lpr mice. Immunol Res 2002; 25: 143-53. (Pubitemid 34264100)
3. Jevnikar AM, Grusby MJ, Glimcher LH,. Prevention of nephritis in major histocompatibility complex class II-deficient MRL-lpr mice. J Exp Med 1994; 179: 1137-43.
4. Merino R, Fossati L, Iwamoto M, Takahashi S, Lemoine R, Ibnou-Zekri N, et al. Effect of long-term anti-CD4 or anti-CD8 treatment on the development of lpr CD4- CD8- double negative T cells and of the autoimmune syndrome in MRL-lpr/lpr mice. J Autoimmun 1995; 8: 33-45.
5. Zhou L, Chong MM, Littman DR,. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009; 30: 646-55.
6. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORÎt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126: 1121-33. (Pubitemid 44380299)
7. Akahoshi M, Nakashima H, Tanaka Y, Kohsaka T, Nagano S, Ohgami E, et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1644-8. (Pubitemid 30263632)
8. Masutani K, Akahoshi M, Tsuruya K, Tokumoto M, Ninomiya T, Kohsaka T, et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001; 44: 2097-106. (Pubitemid 33644053)
9. Peng SL, Moslehi J, Craft J,. Roles of interferon-Î and interleukin-4 in murine lupus. J Clin Invest 1997; 99: 1936-46. (Pubitemid 27175941)
10. Balomenos D, Rumold R, Theofilopoulos AN,. Interferon-Î is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 1998; 101: 364-71. (Pubitemid 28067333)
11. Haas C, Ryffel B, Le Hir M,. IFN-Î is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. J Immunol 1997; 158: 5484-91. (Pubitemid 127681257)
12. Schwarting A, Wada T, Kinoshita K, Tesch G, Kelley VR,. IFN-Î receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J Immunol 1998; 161: 494-503. (Pubitemid 28285560)
13. Carroll JM, Crompton T, Seery JP, Watt FM,. Transgenic mice expressing IFN-Î in the epidermis have eczema, hair hypopigmentation, and hair loss. J Invest Dermatol 1997; 108: 412-22. (Pubitemid 27148275)
14. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 2455-63.
15. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW,. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008; 127: 385-93.
16. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009; 10: 778-85.
17. Kyttaris VC, Zhang Z, Kuchroo VK, Oukka M, Tsokos GC,. Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J Immunol 2010; 184: 4605-9.
18. H-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8: 345-50. (Pubitemid 46745409)
19. Roark CL, Simonian PL, Fontenot AP, Born WK, O'Brien RL,. Î/δ T cells: an important source of IL-17. Curr Opin Immunol 2008; 20: 353-7.
20. Zhang Z, Kyttaris VC, Tsokos GC,. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 2009; 183: 3160-9.
21. Chatham WW, Kimberly RP,. Treatment of lupus with corticosteroids. Lupus 2001; 10: 140-7. (Pubitemid 32410067)
22. Lu L,. Study on effect of Cordyceps sinensis and artemisinin in preventing recurrence of lupus nephritis. Zhongguo Zhongxiyi Jiehe Zazhi 2002; 22: 169-71.
23. Jin O, Zhang H, Gu Z, Zhao S, Xu T, Zhou K, et al. A pilot study of the therapeutic efficacy and mechanism of artesunate in the MRL/lpr murine model of systemic lupus erythematosus. Cell Mol Immunol 2009; 6: 461-7.
24. Wu X, Zhang W, Shi X, An P, Sun W, Wang Z,. Therapeutic effect of artemisinin on lupus nephritis mice and its mechanisms. Acta Biochim Biophys Sin (Shanghai) 2010; 42: 916-23.
25. Wang JX, Tang W, Shi LP, Wan J, Zhou R, Ni J, et al. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Br J Pharmacol 2007; 150: 652-61. (Pubitemid 46355561)
26. Wang JX, Tang W, Zhou R, Wan J, Shi LP, Zhang Y, et al. The new water-soluble artemisinin derivative SM905 ameliorates collagen-induced arthritis by suppression of inflammatory and Th17 responses. Br J Pharmacol 2008; 153: 1303-10. (Pubitemid 351415509)
27. Hou LF, He SJ, Wang JX, Yang Y, Zhu FH, Zhou Y, et al. SM934, a water-soluble derivative of arteminisin, exerts immunosuppressive functions in vitro and in vivo. Int Immunopharmacol 2009; 9: 1509-17.
28. Wang JX, Hou LF, Yang Y, Tang W, Li Y, Zuo JP,. SM905, an artemisinin derivative, inhibited NO and pro-inflammatory cytokine production by suppressing MAPK and NF-ÎB pathways in RAW 264.7 macrophages. Acta Pharmacol Sin 2009; 30: 1428-35.
29. Du C, Liu C, Kang J, Zhao G, Ye Z, Huang S, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol 2009; 10: 1252-9.
30. Tao X, Fan F, Hoffmann V, Longo NS, Lipsky PE,. Therapeutic impact of the ethyl acetate extract of Tripterygium wilfordii Hook F on nephritis in NZB/W F1 mice. Arthritis Res Ther 2006; 8: R24.
31. Khalil M, Inaba K, Steinman R, Ravetch J, Diamond B,. T cell studies in a peptide-induced model of systemic lupus erythematosus. J Immunol 2001; 166: 1667-74. (Pubitemid 32114648)
32. Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, Albesiano E, et al. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007; 179: 4313-7.
33. Kimura A, Naka T, Kishimoto T,. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci U S A 2007; 104: 12099-104. (Pubitemid 47185636)
34. Sakaguchi S, Yamaguchi T, Nomura T, Ono M,. Regulatory T cells and immune tolerance. Cell 2008; 133: 775-87. (Pubitemid 351707693)
35. Monk CR, Spachidou M, Rovis F, Leung E, Botto M, Lechler RI, et al. MRL/Mp CD4+,CD25- T cells show reduced sensitivity to suppression by CD4+,CD25+ regulatory T cells in vitro: a novel defect of T cell regulation in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1180-4. (Pubitemid 40530125)
36. Parietti V, Monneaux F, Decossas M, Muller S,. Function of CD4+,CD25+ Treg cells in MRL/lpr mice is compromised by intrinsic defects in antigen-presenting cells and effector T cells. Arthritis Rheum 2008; 58: 1751-61. (Pubitemid 351847529)
37. Alperovich G, Rama I, Lloberas N, Franquesa M, Poveda R, Goma M, et al. New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus 2007; 16: 18-24. (Pubitemid 46178084)
38. Atkinson C, Qiao F, Song H, Gilkeson GS, Tomlinson S,. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol 2008; 180: 1231-8.
39. Anders HJ, Belemezova E, Eis V, Segerer S, Vielhauer V, Perez de Lema G, et al. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol 2004; 15: 1504-13. (Pubitemid 38679675)
40. Carvalho-Pinto CE, Garcia MI, Mellado M, Rodriguez-Frade JM, Martin-Caballero J, Flores J, et al. Autocrine production of IFN-Î by macrophages controls their recruitment to kidney and the development of glomerulonephritis in MRL/lpr mice. J Immunol 2002; 169: 1058-67. (Pubitemid 34753466)
41. Bagavant H, Deshmukh US, Wang H, Ly T, Fu SM,. Role for nephritogenic T cells in lupus glomerulonephritis: progression to renal failure is accompanied by T cell activation and expansion in regional lymph nodes. J Immunol 2006; 177: 8258-65. (Pubitemid 44846348)